These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26577239)

  • 1. Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
    Haebich G; Mughal A; Tofazzal N
    Clin Exp Dermatol; 2016 Jun; 41(4):433-4. PubMed ID: 26577239
    [No Abstract]   [Full Text] [Related]  

  • 2. Fingolimod (Gilenya) and melanoma.
    Robinson CL; Guo M
    BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 28003234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of a new melanoma in a patient treated with fingolimod.
    Michiels Y; Bugnon O; Michiels JF; Mazellier S
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31036735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary cutaneous CD30
    Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
    Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
    [No Abstract]   [Full Text] [Related]  

  • 6. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
    J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
    [No Abstract]   [Full Text] [Related]  

  • 7. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 9. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Beadnall HN; Gill AJ; Riminton S; Barnett MH
    Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod-associated PML in a patient with prior immunosuppression.
    Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
    Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
    [No Abstract]   [Full Text] [Related]  

  • 13. Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
    Matoula T; Nikolaou V; Marinos L; Katsavos S; Nasis G; Economidi A; Karampidou K; Stratigos A; Antoniou C
    Mult Scler; 2016 Oct; 22(12):1630-1631. PubMed ID: 27053634
    [No Abstract]   [Full Text] [Related]  

  • 14. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 15. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Avasarala J; Jain S; Urrea-Mendoza E
    J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
    Kraemer M; Weber R; Herold M; Berlit P
    Mult Scler; 2015 Oct; 21(11):1473-5. PubMed ID: 26283695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricular arrhythmia in a male MS patient on fingolimod.
    van Pesch V; Marchandise S; El Sankari S; Sindic C
    Acta Neurol Belg; 2015 Mar; 115(1):77-9. PubMed ID: 24710722
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
    Muccilli A; Nehme A; Labrie M; Girard M; Odier C; Poppe AY
    J Neurol Sci; 2019 Aug; 403():119-121. PubMed ID: 31276860
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.
    Navardi S; Sahraian MA; Naser Moghadasi A
    Rev Neurol (Paris); 2020 May; 176(4):289-290. PubMed ID: 31668286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.